[go: up one dir, main page]

ATE339436T1 - Expression von lipoproteinen - Google Patents

Expression von lipoproteinen

Info

Publication number
ATE339436T1
ATE339436T1 AT96918793T AT96918793T ATE339436T1 AT E339436 T1 ATE339436 T1 AT E339436T1 AT 96918793 T AT96918793 T AT 96918793T AT 96918793 T AT96918793 T AT 96918793T AT E339436 T1 ATE339436 T1 AT E339436T1
Authority
AT
Austria
Prior art keywords
protein
lipidated
disclosed
leader sequence
heterologous
Prior art date
Application number
AT96918793T
Other languages
English (en)
Inventor
Robert C Huebner
Lorne F Erdile
Donald J Warakomski
Robert S Becker
Maryanne B Gray
Derek L Pyle
Original Assignee
Sanofi Pasteur Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Inc filed Critical Sanofi Pasteur Inc
Application granted granted Critical
Publication of ATE339436T1 publication Critical patent/ATE339436T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT96918793T 1995-06-07 1996-06-05 Expression von lipoproteinen ATE339436T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47578195A 1995-06-07 1995-06-07
US48637395A 1995-06-07 1995-06-07

Publications (1)

Publication Number Publication Date
ATE339436T1 true ATE339436T1 (de) 2006-10-15

Family

ID=27044930

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96918793T ATE339436T1 (de) 1995-06-07 1996-06-05 Expression von lipoproteinen

Country Status (13)

Country Link
EP (2) EP0832093B1 (de)
JP (1) JP4091112B2 (de)
AT (1) ATE339436T1 (de)
AU (1) AU721954B2 (de)
CA (2) CA2704354A1 (de)
DE (1) DE69636544T2 (de)
DK (1) DK0832093T3 (de)
ES (1) ES2271954T3 (de)
FI (1) FI974422A7 (de)
IL (1) IL118578A (de)
NO (2) NO324089B1 (de)
PT (1) PT832093E (de)
WO (1) WO1996040718A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7008625B2 (en) 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
ZA964896B (en) * 1995-06-07 1997-01-08 Connaught Lab Expression of lipoproteins
AU2313199A (en) 1998-02-03 1999-08-23 Center For Disease Control And Prevention Recombinant lipidated psaa protein, methods of preparation and use
AU2003204215B2 (en) * 1998-02-03 2007-01-11 Aventis Pasteur Recombinant Lipidated PsaA Protein, Methods of Preparation and Use
PT1790660E (pt) * 2000-02-28 2012-09-17 Novartis Vaccines & Diagnostic Expressão heteróloga de proteínas de neisseria
WO2002016421A2 (en) 2000-08-18 2002-02-28 Research Foundation Of The State University Of New York Altered ospa of borrelia burgdorferi
MY144532A (en) 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
PT1812058E (pt) 2004-10-25 2012-09-17 Statens Seruminstitut Antigénios de chlamydia trachomatis para vacina e utilização em diagnóstico
AU2006261445B2 (en) 2005-06-23 2011-03-31 Statens Serum Institut Tuberculosis vaccines comprising antigens expressed during the latent infection phase
TWI367109B (en) 2006-01-19 2012-07-01 Mary Kay Inc Compositions comprising kakadu plum extract or acai berry extract
US20090324638A1 (en) * 2006-06-12 2009-12-31 Biopeptides Corp. Live bacterial vaccine
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
EP2199303B1 (de) 2008-12-12 2013-06-05 Euroimmun Medizinische Labordiagnostika AG Polypeptide und Verfahren zur spezifischen Detektion von Antikörpern bei Patienten mit einer Borrelieninfektion
TR201903223T4 (tr) 2009-04-24 2019-03-21 Statens Seruminstitut Reaktivasyonu önlemek üzere bir tüberküloz TB aşısı.
CA2772626C (en) 2009-08-28 2013-12-10 Mary Kay Inc. Skin care formulations
PL3246044T5 (pl) 2010-08-23 2024-06-17 Wyeth Llc Stabilne preparaty antygenów rLP2086 Neisseria meningitidis
PE20140173A1 (es) 2010-09-10 2014-02-20 Wyeth Llc Variantes no lipidadas de antigenos orf2086 de neisseria meningitidis
EP4043029A1 (de) 2012-03-09 2022-08-17 Pfizer Inc. Neisseria meningitidis-zusammensetzungen und verfahren dafür
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
EP3041502A2 (de) 2013-09-08 2016-07-13 Pfizer Inc. Neisseria meningitidis-zusammensetzungen und verfahren dafür
US10888611B2 (en) 2015-02-19 2021-01-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
JP7010961B2 (ja) 2017-01-31 2022-02-10 ファイザー・インク 髄膜炎菌組成物およびその方法
KR102871663B1 (ko) 2019-09-27 2025-10-16 화이자 인코포레이티드 네이세리아 메닌기티디스 조성물 및 그의 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4624926A (en) * 1981-01-02 1986-11-25 The Research Foundation Of State University Of New York Novel cloning vehicles for polypeptide expression in microbial hosts
CA2032914A1 (en) * 1989-12-26 1991-06-27 Peter C.K. Lau Use of bacterial lipoprotein amino terminus in fusion plasmids for in vivo expression of lipid modified polypeptides
CA2084413A1 (en) * 1990-06-15 1991-12-16 Richard A. Flavell Compositions and methods for the prevention and diagnosis of lyme disease
DK0571538T5 (da) * 1991-02-15 2002-03-04 Uab Research Foundation Strukturgen for pneumokokprotein
DK0650527T3 (da) * 1991-10-22 2003-07-14 Symbicom Ab Forbedring af Borrelia burgdorferidiagnose og -profylakse
WO1994014318A1 (en) * 1992-12-24 1994-07-07 Medimmune, Inc. Method of protection against streptococcus pneumoniae with transformed mycobacteria

Also Published As

Publication number Publication date
EP0832093A1 (de) 1998-04-01
IL118578A (en) 2006-12-31
NO975619L (no) 1998-01-30
CA2223300A1 (en) 1996-12-19
JPH11514841A (ja) 1999-12-21
NO975619D0 (no) 1997-12-04
AU6134396A (en) 1996-12-30
FI974422L (fi) 1998-02-04
EP1741718A2 (de) 2007-01-10
AU721954B2 (en) 2000-07-20
NO324089B1 (no) 2007-08-13
EP0832093B1 (de) 2006-09-13
DE69636544T2 (de) 2007-06-06
CA2704354A1 (en) 1996-12-19
FI974422A7 (fi) 1998-02-04
CA2223300C (en) 2010-07-27
DE69636544D1 (de) 2006-10-26
DK0832093T3 (da) 2007-01-08
NO20064621L (no) 1998-01-30
JP4091112B2 (ja) 2008-05-28
EP0832093A4 (de) 2001-01-03
WO1996040718A1 (en) 1996-12-19
IL118578A0 (en) 1996-10-16
PT832093E (pt) 2006-12-29
ES2271954T3 (es) 2007-04-16
EP1741718A3 (de) 2007-03-28
FI974422A0 (fi) 1997-12-05

Similar Documents

Publication Publication Date Title
ATE339436T1 (de) Expression von lipoproteinen
DK0737207T3 (da) Inhibitorer for humant plasmin afledt af Kunitz-domæner
DE68917323D1 (de) Expressions-Vektor für Fusions-Proteine und Immunogen-Proteine.
IL128590A0 (en) Insecticidal protein toxins from photorhabdus
NL1007028A1 (nl) Stabilisatorcombinatie.
IT8520226A0 (it) Sistema di controllo per motore commutato elettronicamente, sistema di motore commutato elettronicamente, macchina lavabiancheria e metodi per controllare la medesima.
AU4978496A (en) Encapsidated recombinant poliovirus nucleic acid
EP0608120A3 (de) Durchflusssteuerungsvorrichtung für Kapillarelektroforese.
ATE263836T1 (de) Chimere proteine, welche borrelia polypeptide beinhalten, verwendungen dafür
FI972384A7 (fi) Uudet dipeptidiset p-amidinobentsyyliamidit, jotka sisältävät N-termin aalisia sulfonyyli- tai amidinosulfonyyliryhmiä
IT1307309B1 (it) Peptidi stabilizzanti, polipeptidi ed anticorpi che li comprendono.
DK295188D0 (da) Fibronectinbindende protein og fremgangsmaade til fremstilling heraf
NL193766B (nl) Geïsoleerde draad.
ATE223491T1 (de) Verfahren zur reinigung von biomolekül- oder proteinkomplexen
DE19681312T1 (de) Datenverbindungs-Steuerverfahren
HU9202074D0 (en) Collagen binding protein qnd method for producing it
SE9602822D0 (sv) New receptor
FI952738L (fi) Stabiiliproteiini, fosfolipidikoostumuksia ja menetelmiä
EP0612847A3 (de) Antimikrobielle Proteine.
DE59008462D1 (de) Stabilisatordispersionen.
ATE301713T1 (de) Plazentaprotein 13
DK1342729T3 (da) Antistoffer og antisense-molekyler for G-koblet receptor der udviser selektiv affinitet for ATP
DE59000427D1 (de) Antriebsschlupfregelsystem.
NO892948D0 (no) Modifiserte proteiner.
NL1005505A1 (nl) Servobesturingsinrichting.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0832093

Country of ref document: EP